<DOC>
	<DOCNO>NCT00512629</DOCNO>
	<brief_summary>Parenteral nutrition ( PN ) solution life save patient surgical gastrointestinal disease . However , use PN pediatric population , especially premature infant , frequently associate liver injury may ultimately result hepatic failure . In study conduct murine model , observe intravenous fat emulsion ( IFE ) comprise omega-3 fatty acid able prevent development cholestasis , common precursor PN-associated liver disease , well reverse preexist PNALD combination factor , include improve triglyceride clearance couple anti-inflammatory property . In case series treat patient hepatic cholestasis , serum bilirubin level decrease markedly parenteral administration omega-3 fatty acid base fat emulsion ( Omegaven® ) . Patients tolerate therapy adverse reaction attribute use observe . Based result previous study , propose conduct randomize trial aim gain preliminary evidence efficacy omega-3 fatty acid base IFE prevent PNALD child intestinal failure</brief_summary>
	<brief_title>Cholestasis Prevention : Efficacy IV Fish Oil</brief_title>
	<detailed_description>We propose conduct randomize control clinical trial determine whether use omega-3 fatty acid base IFE infant surgical gastrointestinal disease improve clinical outcome compare infant treat standard IFE 6 month post randomization . Neonates infant &lt; 3 month old ( postnatally ) surgical gastrointestinal disease ( defined congenital acquire gastrointestinal disease require PN 21 day ) eligible enrollment . Patients meet inclusion exclusion criterion randomize receive PN either Intralipid® Omegaven® . The appearance IFEs indistinguishable , patient , family medical care team blind treatment group allocation . Aside IFE type , clinical care group infant remain unchanged , include standard use feed advancement protocol , treatment underlying gastrointestinal disease .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>Inclusion criterion ( follow ) : 1 . Congenital acquire gastrointestinal disease require surgical intervention [ Midgut volvulus , Gastroschisis ( know suspect atresia ( ) , perforation ( ) require jejunostomy , bowel resection &gt; 20cm ) , Omphalocele , Jejunal atresia NEC ( peritoneal drain ) duodenal atresia ] ; 2 . Expected dependence parenteral nutrition full partial nutritional support anticipate duration therapy least 21 day ; Subjects judge clinical team require PN support minimum 21 day base follow criterion : inability tolerate enteral feeding , lack audible bowel sound , contraindication initiation enteral feeding ( e.g. , grossly bloody stool sign intestinal ischemia , hypotension , bilious emesis , clinical radiographic evidence bowel obstruction ) ; 3 . Neonates infant &lt; 3 month age ( postnatally ) ; 4 . Gestational age &gt; 28 week ; 5 . Baseline direct bilirubin le 1.0 mg/dL ( normal ) ; 6 . Weight &gt; 1 kg Exclusion criterion ( one follow ) : 1 . Exposure soybean oil fat emulsion great three week ( &gt; 21 day ) time enrollment 2 . Known suspected intolerance allergy component study IFE , include fish , soy egg protein 3 . Inability obtain write informed consent prior baseline lab 4 . The patient enrol clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) 5 . Intention transfer care another patient facility within 3 month baseline labs 6 . Any serum triglyceride level great 400 mg/dL baseline 7 . History severe hemolytic disorder INR great 1.5 baseline ( INR cutoff great 2 baby less 1 week age ) 8 . History shock require vasopressor ( dopamine equal less 20 micrograms/kilogram/minute allow ; use vasopressor exclude ) 9 . Preexisting liver disease , regardless etiology 10 . Hemodynamically unstable judge PI 11 . Renal failure ( creatinine great 0.4 mg/dL unless less 1 month agethen PI 's discretion ) 12 . Patient previously STEP ( Serial Transverse Enteroplasty Procedure ) 13 . Patient currently ECMO nitric oxide 14 . GGTP &gt; 80 mg/L baseline 15 . Weight &lt; 1 kg time enrollment 16 . Gestational age &lt; 28 week time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>PN</keyword>
	<keyword>cholestasis</keyword>
	<keyword>gastrointestinal disease infant</keyword>
	<keyword>short bowel syndrome</keyword>
</DOC>